Cancer Cachexia, Cancer Cachexia Syndrome
Conditions
Keywords
Cancer Cachexia, QLS2319, Cancer Cachexia Syndrome
Brief summary
Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia
Detailed description
This study is a first-in-human, dose-escalation trial in healthy adult participants and cancer cachexia to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of QLS2319. The target population of dose escalation part is healthy adult participants, and the dose expansion part will enroll patients with cancer cachexia.
Interventions
DRUGQLS2319
QLS2319 will be administered via subcutaneous injection
DRUGPlacebo
placebo will be administered via subcutaneous injection
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Ia phase: 1. Male and female subjects aged 18-55 years (inclusive), at the time of signing the ICF.; 2. Body weight ≥ 50 kg for males and ≥ 45 kg for females, with a body mass index (BMI = weight (kg)/height 2 (m) 2) of 18.5-26 kg/m2 (inclusive); 3. Participants (including their partners) who have no plan to become pregnant and voluntarily use effective contraception from screening to 6 months after the last dose; Ib phase: 1. Subjects aged ≥ 18 years at screening; 2. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures; 3. ECOG performance status score of 0, 1; 4. Cancer cachexia documented in medical records; -
Exclusion criteria
Ia phase: 1. Subjects with clinically significant abnormal laboratory findings, or with clinically significant diseases or conditions, who are considered by the investigator to be ineligible for enrollment in this study. 2. History of HIV infection, syphilis, hepatitis B, or hepatitis C; 3. History of recurrent infections or active infections； 4. Subjects who, in the judgment of the investigator, are not suitable for participation in the study. Ib phase: 1. Current active reversible causes of decreased food intake 2. Cachexia caused by other reasons 3. Receiving tube feedings or parenteral nutrition within 28 days prior to the first administration of the investigational product 4. Presence of concomitant conditions, other than neoplastic cachexia, which are deemed by the investigator to cause difficulty in oral intake or malabsorption of ingested food. 5. Subjects with known allergy to QLS2319 or any of its components, or with a history of severe allergic reactions or uncontrolled allergic asthma.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase Ia：Safety and tolerability after a single subcutaneous injection of QLS2319/placebo | Up to Day 99 | Incidence and severity of adverse events (AEs), assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 (v6.0) |
| Phase Ib：Safety and tolerability after multiple subcutaneous injections of QLS2319 | Up to 12 weeks | Incidence and severity of adverse events (AEs), assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 (v6.0) |
Countries
China
Contacts
CONTACTLi Zhang
CONTACTYan Huang
Outcome results
None listed